Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
February 7, 2023 4:01 PM ESTFull year product revenue of $8.93 billion, an 18% increase compared to full year 2021
Full year GAAP and non-GAAP net income increased 42% and 53%, respectively, versus 2021
Company provides full year 2023 product revenue guidance of $9.55 to $9.7 billion
Exa-cel regulatory submissions validated in the EU and U.K.; U.S. rolling BLA submission underway
Advancing broad and diverse clinical pipeline, with multiple clinical milestones expected in 2023
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the... More
